Asset Details
Do you wish to reserve the book?
The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results
Do you wish to request the book?
The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results
2021
Overview
IntroductionAromatase inhibitor (AI)-associated bone loss increases the risk of bone fracture and reduces patients’ quality of life, making it a critical issue worldwide. We conducted a prospective non-randomized clinical trial (UMIN-CTR, UMIN 000016173) to assess the effect of denosumab on bone loss in patients treated with adjuvant AI and have previously reported the results at 12 and 24 months. This study aimed to present the results at 36 months of treatment with denosumab for osteopenia in breast cancer patients who were undergoing treatment with adjuvant AI; 36 months is the longest denosumab treatment period reported so far.Materials and methodsPatients received 60-mg denosumab subcutaneously every 6 months. Daily supplements containing 500-mg elemental calcium and at least 400 international units of vitamin D were highly recommended throughout the study period. The levels of bone mineral density (BMD) and bone turnover markers, serum tartrate-resistant acid phosphatase isoform 5b, and bone alkaline phosphatase were determined at baseline and 6, 12, 18, 24, and 36 months.ResultsAt 36 months, the bone mineral density of the lumbar spine, right femoral neck, and left femoral neck were found to increase by 8.8% (95% confidence interval CI 7.6–10.1), 4.3% (95% CI 3.0–5.5), and 3.1% (95% CI 2.1–4.1), respectively. No non-traumatic clinical fractures occurred in patients receiving AI and denosumab.ConclusionTwice-yearly administration of denosumab to the breast cancer patients treated with adjuvant AI, regardless of the skeletal site, resulted in consistent increases in BMD without severe adverse events at 36 months.
Publisher
Springer Nature B.V
Subject
